A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

NCT02743221 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Trifluridine/tipiracil + bevacizumab
DRUG: Capecitabine + bevacizumab

Sponsor

Institut de Recherches Internationales Servier

Collaborators

[object Object]